Unprecedented opportunities and promise for cancer prevention research

Cancer Prevention Research

Volumn 3, Issue 4, 2010, Pages 394-402

  Blackburn, Elizabeth H ^a   Tlsty, Thea D ^b   Lippman, Scott M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FINASTERIDE; HEPATITIS B VACCINE; MUCIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; SULINDAC; TAMOXIFEN; TUMOR MARKER; TUMOR VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; BEHAVIORAL SCIENCE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER MODEL; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER STEM CELL; CELL TRANSFORMATION; CELLULAR STRESS RESPONSE; CIGARETTE SMOKING; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG TARGETING; ENDOMETRIUM TUMOR; EPITHELIUM CELL; GENE TARGETING; GENETIC EPIGENESIS; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; STOMACH CANCER; TELOMERE; TUMOR GROWTH; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 77950848216     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0051     Document Type: Review

References (104)

1. Tannenbaum A. The genesis and growth of tumors. II. Effects of caloric restriction per se. Cancer Res 1943;3:749-756
2. Hursting SD. Mechanistic insights into reducing the weight of breast cancer. Cancer Prev Res 2009;2:295-297
3. Pollak M. Macronutrient intake and cancer: How does dietary restriction influence tumor growth and why should we care? Cancer Prev Res 2009;2:698-701.
4. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009;301: 39-51.
5. Penney KL, Schumacher FR, Li H, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res. In press, 2010.
6. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-819 (Pubitemid 18048359)
7. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985;16: 796-807.
8. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol Mech Dis 2006;1:119-150
9. Eng C, Leon G, Orlof f MS, Ostrowski MC. Genomic alterations in tumor stroma. Cancer Res 2009;69:6759-6764
10. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76:69-125. (Pubitemid 26048279)
11. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-5011
12. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61. (Pubitemid 19115892)
13. Gandhi L, McNamara KL, Li D, Borgman CL, et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res 2009;2:330-337
14. Wong K-K, Jacks T, Dranof f G. NF-κB fans the flames of lung carcinogenesis. Cancer Prev Res 2010;3:403-405
15. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
16. Issa J-P. Cancer prevention: epigenetics steps up to the plate. Cancer Prev Res 2008;1:219-222
17. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010;31:9-18.
18. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413:432-435 (Pubitemid 32928599)
19. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006;107: 2680-2685
20. Marrone A, Sokhal P, Walne A, et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 2007;92: 1013-1020 (Pubitemid 350144206)
21. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005;366:662-664 (Pubitemid 41176019)
22. Risques RA, Vaughan TL, Li X, et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007;16:2649-2655 (Pubitemid 351210548)
23. Hou L, Savage SA, Blaser MJ, et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:3103-3109
24. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A 2004;101: 17312-17315 (Pubitemid 39627816)
25. Epel ES, Lin J, Wilhelm FH, et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology 2006;31:277-287 (Pubitemid 43261645)
26. Williams JB, Pang D, Delgado B, et al. Model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev Res 2009;2:850-861
27. Hermes GL, Delgado B, Tretiakova M, et al. Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A 2009;106:22393-22398
28. McClintock MK, Conzen SD, Gehlert S, Masi C, Olopade F. Mammary cancer and social interactions: identifying multiple environments that regulate gene expression throughout the life span. J Gerontol B Psychol Sci Soc Sci 2005;60:32-41. (Pubitemid 40502809)
29. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the west of Scotland primary prevention study: a nested case-control study. Lancet 2007;369:107-114
30. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autof luorescence imaging. Cancer Prev Res 2009;2:423-431
31. Gauthier ML, Berman HK, Miller CJ, et al. Abrogated stress response distinguishes basal-like tumors and DCIS lesions associated with subsequent tumor events. Cancer Cell 2007;12:479-491
32. Berman HK, Gauthier ML, Tlsty TD. Premalignant breast neoplasia: a paradigm of inter- and intralesional molecular heterogeneity and its biological and clinical ramifications. Cancer Prev Res. In press, 2010.
33. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010; 362:986-993
34. Li Y, Sheu C-C, Ye Y, et al. GPC5 genetic variants are associated with lung cancer risk in never smokers. Lancet Oncol. In press, 2010.
35. Beane J, Sebastiani P, Whitfield TH, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res 2008;1:56-64.
36. Varella-Garcia M, Schulte AP, Wolf HJ, et al. The detection of chromosomal aneusomy by fish in sputum predicts lung cancer incidence. Cancer Prev Res 2010;3:447-453
37. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res 2009;2:617-624
38. Lipkin SM, Chao L, Moreno V, et al. Genetic variation in HMG-CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res. In press, 2010.
39. Hammond SL, Ham RG, Stampfer MR. Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended passage with pituitary extract. Proc Natl Acad Sci U S A 1984;81:5435-5439
40. Band V, Sager R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci U S A 1989; 86:1249-1253 (Pubitemid 19061524)
41. Walen KH, Stampfer MR. Chromosome analyses of human mammary epithelial cells at stages of chemical-induced transformation progression to immortality. Cancer Genet Cytogenet 1989;37:249-261
42. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumor cells with defined genetic elements. Nature 1999;400:464-468
43. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001; 409:633-637 (Pubitemid 32154817)
44. Crawford YP, Gauthier M, Joubel A, et al. Histologically normal human mammary epithelia with silenced p16INK4a overexpress COX-2, promoting a premalignant program. Cancer Cell 2004;5:263-273 (Pubitemid 38402118)
45. Fordyce C, Fessenden T, Pickering C, et al. DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res 2010;3:190-201.
46. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90: 1371-1388 (Pubitemid 28439961)
47. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741 (Pubitemid 43920726)
48. Lippman SM, Brown PH. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 1999;91:1809-1819
49. Lathrop AE, Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res 1916;1:1-19.
50. Lynch HT, Harris RE, Organ CH, Jr., et al. The surgeon, genetics, and cancer control: the Cancer Family Syndrome. Ann Surg 1977; 185:435-440 (Pubitemid 8069870)
51. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622 (Pubitemid 34755669)
52. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-269 (Pubitemid 43113031)
53. Tof t D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A 1966;55:1574-1581
54. Jordan VC. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanth racene (DMBA-induced rat mammary carcinoma model. J Steroid Biochem 1974;5:354.
55. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224 (Pubitemid 36859473)
56. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of highgrade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008;1:174-181
57. Andriole GL, Pettaway CA, TC, ILF, Somerville MC. Incidence of biopsy-detectable prostate cancer in the REduction of DUtasteride of Prostate Cancer Events (REDUCE) trial: Blinded 2-year results (abstract #2207). Presented at the Annual Meeting of the American Urological Association, Chicago (IL). 2009.
58. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297
59. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952 (Pubitemid 30419089)
60. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899 (Pubitemid 36297997)
61. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355: 873-884 (Pubitemid 44315980)
62. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-1613 (Pubitemid 46710123)
63. Winawer SJ, Zauber AG, Ho MN, et al, The National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329:1977-1981
64. Eberhart CE, Cof fey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188
65. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809
66. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356: 2131-2142
67. Chan AT, Zauber AG, Hsu M, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009;136:2127-2136
68. Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-7864
69. Shureiqi I, Jiang W, Zuo X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 2003; 100:9968-9973
70. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res 2008;1:93-99
71. Duffield-Lillico AJ, Boyle JO, Zhou XK, et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009;2: 322-329
72. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarker Prev 2010;19: 443-446
73. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-38
74. Sporn MB. Combination chemoprevention of cancer. Nature 1980; 287:107-108
75. Seager CM, Puzio-Kuter AM, Patel T, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res 2009;2:1008-1014
76. Zhang Lf, Ren X, Alt E, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. In press, 2010.
77. Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prev Res 2010;3:410-415
78. Chang MH, Chen CJ, Lai MS, et al, Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-1859
79. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-1355
80. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967;66:924-931
81. Blumberg BS. Bioethical questions related to hepatitis B antigen. Am J Clin Pathol 1976;65:848-853
82. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927
83. Koutsky L. The epidemiology behind the HPV vaccine discovery. Ann Epidemiol 2009;19:239-244
84. Schiffman M, Wacholder S. From India to the world-a better way to prevent cervical cancer. N Engl J Med 2009;360:1453-1455
85. zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW. Attempts to detect virus-secific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer 1974;13:650-656
86. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983;80:3812-3815
87. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956
88. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009;2:776-781
89. Disis ML. The ultimate in cancer chemoprevention: cancer vaccines. Cancer Prev Res 2010;3:406-409
90. Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res 2010;3:438-446
91. Kenter GG, Welters MJP, Valentijn ARPM, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-1847
92. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 2008;372:392-397
93. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-1315
94. Blaser MJ. Understanding microbe-induced cancers. Cancer Prev Res 2008;1:15-20.
95. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;22:1096-100, 319.
96. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950;2:739-748
97. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J Am Med Assoc 1950;143:329-336
98. Auerbach O, Forman JB, Gere JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung;a report of progress. N Engl J Med 1957;256:97-104.
99. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004;101:10143-10148 (Pubitemid 38891209)
100. Schembri F, Sridhar S, Perdomo C, et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci U S A 2009;106:2319-2324
101. Boyle JO, Gümüş ZH, Kacker A, et al. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res 2010;3: 266-278
102. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking-a study of male twins. N Engl J Med 1992;327:829-833
103. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009; 5:200-205
104. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006;12:1133-1138